HSIC

ANALYST NOTE: HSIC (Henry Schein, Inc.) Date: 2026-06-13 Event Date: 2026-06-13

1. Structural Readiness

As of the close on 2026-06-13, Henry Schein, Inc. presents a confirmed coil setup. The breakout signal has fired, and the setup is currently actionable.

• Conservative Entry: $89.59
• Breakout Level: The setup requires a close above the consolidation range defined by the conservative entry of $89.59 to confirm the structural integrity of the breakout.
• Current Price: $88.23
• Extension: The stock is currently trading at a -1.5% extension relative to the conservative entry level.
• Setup Status: The coil is confirmed. While the price is currently slightly below the conservative entry threshold, the structural quality is validated by the ATR metrics. The ATR at breakout was 2.6% (productive), and the current ATR remains 2.6% (productive). This indicates structural quality at the setup and appropriate volatility for position sizing. The absence of a current close above $89.59 does not invalidate the setup; it indicates the market is testing the breakout level.

2. The Thesis Layer

At this date, HSIC is classified as a TACTICAL, setup-led name. There is no named secular thesis attached to this specific setup in the current evidence base. The conviction for this position must be derived strictly from the quality of the technical setup (the confirmed coil) and the immediate business fundamentals provided in the recent earnings and filings, rather than a broad macroeconomic narrative. We judge this name on the alignment of its structural readiness with its operational execution.

3. The Business

Henry Schein, Inc. operates as a global distributor of healthcare products and services, serving over one million customers worldwide. The company's operations are organized into two principal segments: Health Care Distribution and Technology and Value-Added Services.

• Distribution Model: The company markets and sells a comprehensive selection of over 300,000 branded and corporate brand products. This includes dental consumables (infection control, composites, anesthetics), specialized equipment (handpieces, X-ray machinery), and medical supplies (pharmaceuticals, surgical instruments, vaccines).
• Customer Base: As of the 2026-05-05 earnings transcript, the company serves hundreds of thousands of independent private practices and is the primary distributor for most national Dental Service Organizations (DSOs) in the U.S. The customer base extends to laboratories, physician practices, ambulatory surgery centers, government entities, and home health providers.
• Technology & Services: The company has expanded its footprint in software and value-added services. As of the 2026-05-05 transcript, cloud-based customers increased by roughly 25% year-over-year, with over 13,000 Dentrix Ascend and Dentale subscribers. The company also operates 127 equipment sales and service centers globally.
• Strategic Initiatives: Management is executing a plan to achieve greater than $200 million of annual operating income improvement within the next few years, with a target of $125 million run rate by the end of 2026. This plan is expected to be completed by the end of 2027.

4. The Archetype and Conviction

Archetype: Quality Compounder. Fit: The name fits the "Quality Compounder" archetype due to its consistent execution of margin expansion, its dominant market position in a fragmented industry, and its successful integration of technology (cloud-based software) into its distribution model.

Valuation and Fundamentals Context:

• Guidance: Management guidance recorded on 2026-05-05 expects 2026 full-year total sales growth of approximately 3% to 5% over 2025.
• Earnings Expectations: Management expects non-GAAP diluted EPS for 2026 to be in the range of $5.23 to $5.37.
• Financial Spine: Forward consensus EPS for FY1 is 5.34642 and FY2 is 5.90788, indicating a complete financial spine coverage.
• Conviction Drivers:
• Margin Inflection: The commitment to $125 million in operating income run rate by end-2026 suggests a clear path to margin expansion.
• Market Share: The position as the primary distributor for most national DSOs and the growth in cloud-based customers (25% YoY) indicate market share gains.
• Structural Quality: The ATR of 2.6% is in the "productive" bucket, suggesting the stock has the volatility necessary for a meaningful move without being in the "extreme" risk zone.
• Rerating Potential: The combination of accelerating internal sales growth (noted in Q2 2026 earnings context) and the successful execution of the value-creation program supports a potential rerating.

5. Invalidation, Strengthening, and Gaps

What Would Strengthen the Case:

• Confirmation of a close above the conservative entry of $89.59, validating the breakout.
• Continued acceleration in cloud-based customer growth beyond the 25% YoY rate reported in May 2026.
• Successful realization of the $125 million operating income run rate by the end of 2026.

What Would Invalidate the Case:

• A sustained failure to break above the $89.59 level combined with a deterioration in the 3-5% sales growth guidance.
• A significant deviation from the projected EPS range of $5.23-$5.37 for 2026.
• Disruption in the supply chain or a loss of key DSO contracts, which would undermine the "trusted partner" narrative.

Gaps in Evidence:

• Missing Evidence: There is no specific evidence provided regarding the *current* quarter's (Q2 2026) actual results as of the 2026-06-13 date, other than the forward-looking guidance and the Q2 earnings call transcript dated 2026-08-04 (which is a future date relative to the event date of 2026-06-13 in the provided evidence list, suggesting the evidence list contains future-dated news items that are not yet available as of the event date). *Correction:* The evidence list contains items dated 2026-08-04, which is *after* the event date of 2026-06-13. As an analyst reasoning *as of* 2026-06-13, I must treat the August 2026 news items as missing evidence or future speculation and cannot use them to validate the current state. The most recent *available* evidence as of 2026-06-13 is the 2026-05-05 earnings transcript and the 2026-02-24 filing.
• Revised Gap: The specific Q2 2026 actual results (reported in August 2026 in the evidence list) are not yet available as of 2026-06-13. The analyst must rely on the May 2026 guidance and the structural setup. The "news" items from August 2026 regarding Q2 earnings beats and raised guidance are not available as of the event date and must be excluded from the current analysis.

PRIVATE ANALYST CALL

Judgment: Buy Confidence: medium Key evidence: Confirmed coil setup with productive ATR (2.6%); Management guidance for $125M operating income run rate by end-2026; Strong cloud-based customer growth (25% YoY) and primary DSO distributor status. Key risks: Current price (-1.5%) is below conservative entry ($89.59) requiring a breakout confirmation; Q2 2026 actual results are not yet available as of this date; Execution risk on the 2027 completion of the value-creation plan. Rating boundary: This is rated Buy rather than Strong Buy because the current price is below the conservative entry level, meaning the breakout is not yet fully confirmed by a close above $89.59. A Strong Buy would require a confirmed close above the entry level. It is not rated Hold because the structural setup is confirmed and the fundamentals support the thesis, but the price action requires a final confirmation step. Sizing hint: Position size should be calibrated to the 2.6% ATR, allowing for the volatility inherent in the breakout test. Expected path: Management expects the value-creation plan to drive operating income improvement, with the $125M run rate target by end-2026. The stock is expected to move higher if it clears the $89.59 resistance, supported by the structural quality of the setup. Expected horizon: 3 to 6 months for the setup to fully resolve and the thesis to play out. Failure mode to watch: A sustained close below the consolidation base without a breakout, indicating a failure of the structural setup.